Skip to main content
. Author manuscript; available in PMC: 2016 Jan 17.
Published in final edited form as: Science. 2015 Jul 2;349(6245):320–324. doi: 10.1126/science.aab3886

Figure 4. Protective efficacy of the Ad/Env HIV-1 vaccine against repetitive, intrarectal SHIV-SF162P3 challenges.

Figure 4

(A) Number of challenges required for acquisition of infection in each vaccine group. (B) Statistical analyses include the hazard ratio with 95% confidence interval and the per exposure reduction of acquisition risk in each group, with P-values reflecting Cox proportional hazard models and log-rank tests. Additional statistical analyses include the percentage of completely protected animals at the end of the challenge series, with P-values reflecting chi-square tests and Fisher’s exact tests.